Boston Scientific reported strong revenue and EPS growth, driven by standout performances in operational regions and the electrophysiology segment. However, there were challenges in the Neuromodulation segment and a temporary pause in the AVANT GUARD trial. Despite these issues, the company's financial outlook remains positive.

Company Guidance

During the Q3 2024 earnings call, Boston Scientific provided robust guidance, reflecting strong performance across its business units. The company reported a 19% growth in operational sales and an 18% increase in organic sales, surpassing the guidance range of 13% to 15%. Adjusted EPS rose by 27% to $0.63, exceeding the guidance range of $0.57 to $0.59, with an adjusted operating margin of 27.2%. For Q4, Boston Scientific anticipates organic growth between 14% and 16%, raising its full-year guidance to approximately 15% growth. The Q4 adjusted EPS is projected to be between $0.64 and $0.66, with a full-year adjusted EPS expectation of $2.45 to $2.47, indicating a growth of 20% to 21%. Key growth areas include the Electrophysiology segment, with sales surging 177%, and innovative products like FARAPULSE and WATCHMAN contributing significantly to the momentum.

Record-Breaking Revenue Growth

Boston Scientific reported a total company operational sales growth of 19% and organic sales growth of 18% in Q3 2024, exceeding the guidance range of 13% to 15%.

Strong Regional Performance

The U.S. market grew 24% operationally, with double-digit growth in 6 of 8 business units. Europe, Middle East, and Africa grew 14%, and Asia Pacific experienced 12% growth, particularly in China, Australia, and New Zealand.

Electrophysiology Segment Surge

Electrophysiology sales grew by an exceptional 177% driven by the success of FARAPULSE, which has now treated over 125,000 patients globally.

Positive Earnings Per Share (EPS) Growth

Adjusted EPS for Q3 2024 was $0.63, representing a growth of 27%, surpassing the guidance range of $0.57 to $0.59.

---

Boston Scientific (BSX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BSX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jan 29, 2025	2024 (Q4)	0.66 / -	0.55	―	―	―
Oct 23, 2024	2024 (Q3)	0.59 / 0.63	0.5	26.00% (+0.13)
Jul 24, 2024	2024 (Q2)	0.58 / 0.62	0.53	16.98% (+0.09)
Apr 24, 2024	2024 (Q1)	0.51 / 0.56	0.47	19.15% (+0.09)
Jan 31, 2024	2023 (Q4)	0.51 / 0.55	0.45	22.22% (+0.10)
Oct 26, 2023	2023 (Q3)	0.48 / 0.50	0.43	16.28% (+0.07)
Jul 27, 2023	2023 (Q2)	0.49 / 0.53	0.44	20.45% (+0.09)
Apr 26, 2023	2023 (Q1)	0.43 / 0.47	0.39	20.51% (+0.08)
Feb 01, 2023	2022 (Q4)	0.47 / 0.45	0.45	0.00% (0.00)
Oct 26, 2022	2022 (Q3)	0.44 / 0.43	0.41	4.88% (+0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

BSX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Oct 23, 2024	$88.01	$87.45	-0.64%
Jul 24, 2024	$78.59	$77.76	-1.06%
Apr 24, 2024	$68.99	$72.91	+5.68%
Jan 31, 2024	$61.42	$63.26	+3.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---